Business context and reporting period
Immunome, Inc. reported a material agreement with Bristol-Myers Squibb Company (BMS), entered into on October 2, 2026. This is a transaction-focused Form 8-K, not a periodic financial report.
Key financial and transaction details
- Immunome paid BMS $20.0 million in cash and issued 4,425,487 common shares as consideration for amending the license agreement.
- The filing does not state the value of the shares or the transaction’s effect on cash balances, liquidity, or financial results.
- The filing provides no revenue, profit, cash-flow, margin, or debt metrics.
Material changes
- The amendment removes Immunome’s future milestone and royalty payment obligations under the license agreement and assigns Immunome patent rights related to varegacestat (formerly AL102) and AL101, previously licensed to it.
- After paying the stated consideration, Immunome has no milestone, royalty, or other payment obligations to BMS under the license agreement or amendment.
- The share issuance was made in an unregistered transaction under Securities Act Section 4(a)(2); the shares may be resold only under an effective registration statement or an applicable exemption.
Obligations, risks, and outlook
- Immunome agreed to use commercially reasonable efforts to file a resale registration statement by November 16, 2026, and to seek effectiveness within the deadlines specified in the agreement.
- Immunome also agreed to certain indemnification obligations and to pay specified fees and expenses related to its registration obligations.
- The filing provides no operating guidance or broader business outlook. The cash payment and share issuance are the principal disclosed financial commitments; the filing does not quantify their effect on liquidity or dilution.
Important facts to verify
- Review the full Amendment No. 4 and Stock Issuance Agreement, including terms omitted from the filing’s summaries.
- Confirm completion and timing of the resale registration statement, and assess the potential resale and dilution impact of the 4,425,487 shares.
- Assess the $20.0 million cash payment against Immunome’s available liquidity and other planned uses of cash.